MRx-4DP0004
- Generic Name
- MRx-4DP0004
- Drug Type
- Biotech
- Background
MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- 4D pharma plc
- Registration Number
- NCT04363372
- Locations
- π¬π§
University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
A Study of MRx-4DP0004 in Asthma
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 34
- Registration Number
- NCT03851250
- Locations
- π¬π§
4D Site Leicester, Leicester, United Kingdom
π¬π§4D Site Manchester, Manchester, United Kingdom
π¬π§Bradford Teaching Hospital, Bradford, West Yorkshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath